MicroRNAs belong to a group of short non-coding RNA molecules that are involved in the regulation of gene expression at multiple levels. Their function was described two decades ago, and, since then, microRNAs have become a rapidly developing field of research. Their participation in the regulation of cellular processes, such as proliferation, apoptosis, cell growth, and migration, made microRNAs attractive for cancer research. Moreover, as a single microRNA can simultaneously target multiple molecules, microRNAs offer a unique advantage in regulating multiple cellular processes in different cell types. Many of these cell types are tumor cells and the cells of the immune system. One of the most studied microRNAs in the context of cancer and the immune system is miR-155. MiR-155 plays a role in modulating innate and adaptive immune mechanisms in distinct immune cell types. As such, miR-155 can be part of the communication between the tumor and immune cells and thus impact the process of tumor immunoediting. Several studies have already revealed its effect on antitumor immune responses, and the targeting of this molecule is increasingly implemented in cancer immunotherapy. In this review, we discuss the current knowledge of miR-155 in the regulation of antitumor immunity and the shaping of the tumor microenvironment, and the plausible implementation of miR-155 targeting in cancer therapy.

Department of Immunology 2nd Faculty of Medicine Charles University and Motol University Hospital 150 06 Prague Czech Republic

Laboratory of Immunotherapy Institute of Microbiology of the Czech Academy of Sciences 142 20 Prague Czech Republic

See more in PubMed

Abbott M., Ustoyev Y. Cancer and the Immune System: The History and Background of Immunotherapy. Semin. Oncol. Nurs. 2019;35:150923. doi: 10.1016/j.soncn.2019.08.002. PubMed DOI

Denaro N., Merlano M.C., Lo Nigro C. Long noncoding RNAs as regulators of cancer immunity. Mol. Oncol. 2019;13:61–73. doi: 10.1002/1878-0261.12413. PubMed DOI PMC

Papaioannou E., Gonzalez-Molina M.D.P., Prieto-Munoz A.M., Gamez-Reche L., Gonzalez-Martin A. Regulation of Adaptive Tumor Immunity by Non-Coding RNAs. Cancers. 2021;13:5651. doi: 10.3390/cancers13225651. PubMed DOI PMC

Bueno M.J., Perez de Castro I., Malumbres M. Control of cell proliferation pathways by microRNAs. Cell Cycle. 2008;7:3143–3148. doi: 10.4161/cc.7.20.6833. PubMed DOI

Yang B.F., Lu Y.J., Wang Z.G. MicroRNAs and apoptosis: Implications in the molecular therapy of human disease. Clin. Exp. Pharmacol. Physiol. 2009;36:951–960. doi: 10.1111/j.1440-1681.2009.05245.x. PubMed DOI

De Paolis V., Lorefice E., Orecchini E., Carissimi C., Laudadio I., Fulci V. Epitranscriptomics: A New Layer of microRNA Regulation in Cancer. Cancers. 2021;13:3372. doi: 10.3390/cancers13133372. PubMed DOI PMC

Yi M., Xu L., Jiao Y., Luo S., Li A., Wu K. The role of cancer-derived microRNAs in cancer immune escape. J. Hematol. Oncol. 2020;13:25. doi: 10.1186/s13045-020-00848-8. PubMed DOI PMC

Pottoo F.H., Iqubal A., Iqubal M.K., Salahuddin M., Rahman J.U., AlHajri N., Shehadeh M. miRNAs in the Regulation of Cancer Immune Response: Effect of miRNAs on Cancer Immunotherapy. Cancers. 2021;13:6145. doi: 10.3390/cancers13236145. PubMed DOI PMC

Rani V., Sengar R.S. Biogenesis and mechanisms of microRNA-mediated gene regulation. Biotechnol. Bioeng. 2022;119:685–692. doi: 10.1002/bit.28029. PubMed DOI

Zhang H.M., Kuang S., Xiong X., Gao T., Liu C., Guo A.Y. Transcription factor and microRNA co-regulatory loops: Important regulatory motifs in biological processes and diseases. Brief. Bioinform. 2015;16:45–58. doi: 10.1093/bib/bbt085. PubMed DOI

Alexander M., Hu R., Runtsch M.C., Kagele D.A., Mosbruger T.L., Tolmachova T., Seabra M.C., Round J.L., Ward D.M., O’Connell R.M. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat. Commun. 2015;6:7321. doi: 10.1038/ncomms8321. PubMed DOI PMC

Acunzo M., Romano G., Wernicke D., Croce C.M. MicroRNA and cancer—A brief overview. Adv. Biol. Regul. 2015;57:7321. doi: 10.1016/j.jbior.2014.09.013. PubMed DOI

Dexheimer P.J., Cochella L. MicroRNAs: From Mechanism to Organism. Front. Cell Dev. Biol. 2020;8:409. doi: 10.3389/fcell.2020.00409. PubMed DOI PMC

Li Z., Xu R., Li N. MicroRNAs from plants to animals, do they define a new messenger for communication? Nutr. Metab. 2018;15:68. doi: 10.1186/s12986-018-0305-8. PubMed DOI PMC

Mishra R., Kumar A., Ingle H., Kumar H. The Interplay Between Viral-Derived miRNAs and Host Immunity During Infection. Front. Immunol. 2019;10:3079. doi: 10.3389/fimmu.2019.03079. PubMed DOI PMC

Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–854. doi: 10.1016/0092-8674(93)90529-Y. PubMed DOI

Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75:855–862. doi: 10.1016/0092-8674(93)90530-4. PubMed DOI

Meister G., Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004;431:343–349. doi: 10.1038/nature02873. PubMed DOI

Hutvagner G., Zamore P.D. A microRNA in a multiple-turnover RNAi enzyme complex. Science. 2002;297:2056–2060. doi: 10.1126/science.1073827. PubMed DOI

Mourelatos Z., Dostie J., Paushkin S., Sharma A., Charroux B., Abel L., Rappsilber J., Mann M., Dreyfuss G. miRNPs: A novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev. 2002;16:720–728. doi: 10.1101/gad.974702. PubMed DOI PMC

Tang G. siRNA and miRNA: An insight into RISCs. Trends Biochem. Sci. 2005;30:106–114. doi: 10.1016/j.tibs.2004.12.007. PubMed DOI

Valencia-Sanchez M.A., Liu J., Hannon G.J., Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–524. doi: 10.1101/gad.1399806. PubMed DOI

Mohr A.M., Mott J.L. Overview of microRNA biology. Semin. Liver Dis. 2015;35:3–11. doi: 10.1055/s-0034-1397344. PubMed DOI PMC

Lai E.C. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet. 2002;30:363–364. doi: 10.1038/ng865. PubMed DOI

Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat. Rev. Genet. 2008;9:102–114. doi: 10.1038/nrg2290. PubMed DOI

Guo H., Ingolia N.T., Weissman J.S., Bartel D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466:835–840. doi: 10.1038/nature09267. PubMed DOI PMC

Henke J.I., Goergen D., Zheng J., Song Y., Schuttler C.G., Fehr C., Junemann C., Niepmann M. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J. 2008;27:3300–3310. doi: 10.1038/emboj.2008.244. PubMed DOI PMC

Moretti F., Thermann R., Hentze M.W. Mechanism of translational regulation by miR-2 from sites in the 5′ untranslated region or the open reading frame. RNA. 2010;16:2493–2502. doi: 10.1261/rna.2384610. PubMed DOI PMC

Catalanotto C., Cogoni C., Zardo G. MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions. Int. J. Mol. Sci. 2016;17:1712. doi: 10.3390/ijms17101712. PubMed DOI PMC

Salmanidis M., Pillman K., Goodall G., Bracken C. Direct transcriptional regulation by nuclear microRNAs. Int. J. Biochem. Cell Biol. 2014;54:304–311. doi: 10.1016/j.biocel.2014.03.010. PubMed DOI

Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433:769–773. doi: 10.1038/nature03315. PubMed DOI

Slack F.J. Regulatory RNAs and the demise of ‘junk’ DNA. Genome Biol. 2006;7:328. doi: 10.1186/gb-2006-7-9-328. PubMed DOI PMC

Lagos-Quintana M., Rauhut R., Yalcin A., Meyer J., Lendeckel W., Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 2002;12:735–739. doi: 10.1016/S0960-9822(02)00809-6. PubMed DOI

Londin E., Loher P., Telonis A.G., Quann K., Clark P., Jing Y., Hatzimichael E., Kirino Y., Honda S., Lally M., et al. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proc. Natl. Acad. Sci. USA. 2015;112:E1106–E1115. doi: 10.1073/pnas.1420955112. PubMed DOI PMC

Bartel D.P. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. doi: 10.1016/S0092-8674(04)00045-5. PubMed DOI

Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303:83–86. doi: 10.1126/science.1091903. PubMed DOI

Lee Y., Jeon K., Lee J.T., Kim S., Kim V.N. MicroRNA maturation: Stepwise processing and subcellular localization. EMBO J. 2002;21:4663–4670. doi: 10.1093/emboj/cdf476. PubMed DOI PMC

Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., Lee J., Provost P., Radmark O., Kim S., et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425:415–419. doi: 10.1038/nature01957. PubMed DOI

Denli A.M., Tops B.B., Plasterk R.H., Ketting R.F., Hannon G.J. Processing of primary microRNAs by the Microprocessor complex. Nature. 2004;432:231–235. doi: 10.1038/nature03049. PubMed DOI

Yi R., Qin Y., Macara I.G., Cullen B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 2003;17:3011–3016. doi: 10.1101/gad.1158803. PubMed DOI PMC

Hammond S.M., Boettcher S., Caudy A.A., Kobayashi R., Hannon G.J. Argonaute2, a link between genetic and biochemical analyses of RNAi. Science. 2001;293:1146–1150. doi: 10.1126/science.1064023. PubMed DOI

Saito K., Ishizuka A., Siomi H., Siomi M.C. Processing of pre-microRNAs by the Dicer-1-Loquacious complex in Drosophila cells. PLoS Biol. 2005;3:e235. doi: 10.1371/journal.pbio.0030235. PubMed DOI PMC

Cheloufi S., Dos Santos C.O., Chong M.M., Hannon G.J. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010;465:584–589. doi: 10.1038/nature09092. PubMed DOI PMC

Cifuentes D., Xue H., Taylor D.W., Patnode H., Mishima Y., Cheloufi S., Ma E., Mane S., Hannon G.J., Lawson N.D., et al. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science. 2010;328:1694–1698. doi: 10.1126/science.1190809. PubMed DOI PMC

Kertesz M., Iovino N., Unnerstall U., Gaul U., Segal E. The role of site accessibility in microRNA target recognition. Nat. Genet. 2007;39:1278–1284. doi: 10.1038/ng2135. PubMed DOI

Wu W., Sun M., Zou G.M., Chen J. MicroRNA and cancer: Current status and prospective. Int. J. Cancer. 2007;120:953–960. doi: 10.1002/ijc.22454. PubMed DOI

Shenouda S.K., Alahari S.K. MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28:369–378. doi: 10.1007/s10555-009-9188-5. PubMed DOI

Oliveto S., Mancino M., Manfrini N., Biffo S. Role of microRNAs in translation regulation and cancer. World J. Biol. Chem. 2017;8:45–56. doi: 10.4331/wjbc.v8.i1.45. PubMed DOI PMC

Condrat C.E., Thompson D.C., Barbu M.G., Bugnar O.L., Boboc A., Cretoiu D., Suciu N., Cretoiu S.M., Voinea S.C. miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis. Cells. 2020;9:276. doi: 10.3390/cells9020276. PubMed DOI PMC

Karimzadeh M.R., Pourdavoud P., Ehtesham N., Qadbeigi M., Asl M.M., Alani B., Mosallaei M., Pakzad B. Regulation of DNA methylation machinery by epi-miRNAs in human cancer: Emerging new targets in cancer therapy. Cancer Gene Ther. 2021;28:157–174. doi: 10.1038/s41417-020-00210-7. PubMed DOI

Shah V., Shah J. Recent trends in targeting miRNAs for cancer therapy. J. Pharm. Pharmacol. 2020;72:1732–1749. doi: 10.1111/jphp.13351. PubMed DOI

Sohrabi B., Dayeri B., Zahedi E., Khoshbakht S., Nezamabadi Pour N., Ranjbar H., Davari Nejad A., Noureddini M., Alani B. Mesenchymal stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy. Cancer Gene Ther. 2022;29:1105–1116. doi: 10.1038/s41417-022-00427-8. PubMed DOI

Bauer K.M., Round J.L., O’Connell R.M. No small matter: Emerging roles for exosomal miRNAs in the immune system. FEBS J. 2022;289:4021–4037. doi: 10.1111/febs.16052. PubMed DOI PMC

Wang D., Wang X., Song Y., Si M., Sun Y., Liu X., Cui S., Qu X., Yu X. Exosomal miR-146a-5p and miR-155-5p promote CXCL12/CXCR7-induced metastasis of colorectal cancer by crosstalk with cancer-associated fibroblasts. Cell Death Dis. 2022;13:380. doi: 10.1038/s41419-022-04825-6. PubMed DOI PMC

Di Martino M.T., Riillo C., Scionti F., Grillone K., Polera N., Caracciolo D., Arbitrio M., Tagliaferri P., Tassone P. miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy. Cancers. 2021;13:1587. doi: 10.3390/cancers13071587. PubMed DOI PMC

O’Connell R.M., Kahn D., Gibson W.S., Round J.L., Scholz R.L., Chaudhuri A.A., Kahn M.E., Rao D.S., Baltimore D. MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 2010;33:607–619. doi: 10.1016/j.immuni.2010.09.009. PubMed DOI PMC

Xiao C., Rajewsky K. MicroRNA control in the immune system: Basic principles. Cell. 2009;136:26–36. doi: 10.1016/j.cell.2008.12.027. PubMed DOI

Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004;22:329–360. doi: 10.1146/annurev.immunol.22.012703.104803. PubMed DOI

Cortez M.A., Anfossi S., Ramapriyan R., Menon H., Atalar S.C., Aliru M., Welsh J., Calin G.A. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019;58:244–253. doi: 10.1002/gcc.22725. PubMed DOI PMC

Nguyen H.T., Phung C.D., Tran T.H., Pham T.T., Pham L.M., Nguyen T.T., Jeong J.H., Choi H.G., Ku S.K., Yong C.S., et al. Manipulating immune system using nanoparticles for an effective cancer treatment: Combination of targeted therapy and checkpoint blockage miRNA. J. Control. Release Off. J. Control. Release Soc. 2021;329:524–537. doi: 10.1016/j.jconrel.2020.09.034. PubMed DOI

Catela Ivkovic T., Voss G., Cornella H., Ceder Y. microRNAs as cancer therapeutics: A step closer to clinical application. Cancer Lett. 2017;407:113–122. doi: 10.1016/j.canlet.2017.04.007. PubMed DOI

Zuo W.N., Zhu H., Li L.P., Jin A.Y., Wang H.Q. MiR-155 promotes proliferation and inhibits apoptosis of nasopharyngeal carcinoma cells through targeting PTEN-PI3K/AKT pathway. Eur. Rev. Med. Pharmacol. Sci. 2019;23:7935–7942. doi: 10.26355/eurrev_201909_19009. PubMed DOI

Witten L., Slack F.J. miR-155 as a novel clinical target for hematological malignancies. Carcinogenesis. 2020;41:2–7. doi: 10.1093/carcin/bgz183. PubMed DOI

Tam W. Identification and characterization of human BIC, a gene on chromosome 21 that encodes a noncoding RNA. Gene. 2001;274:157–167. doi: 10.1016/S0378-1119(01)00612-6. PubMed DOI

Georgantas R.W., 3rd, Hildreth R., Morisot S., Alder J., Liu C.G., Heimfeld S., Calin G.A., Croce C.M., Civin C.I. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control. Proc. Natl. Acad. Sci. USA. 2007;104:2750–2755. doi: 10.1073/pnas.0610983104. PubMed DOI PMC

Masaki S., Ohtsuka R., Abe Y., Muta K., Umemura T. Expression patterns of microRNAs 155 and 451 during normal human erythropoiesis. Biochem. Biophys. Res. Commun. 2007;364:509–514. doi: 10.1016/j.bbrc.2007.10.077. PubMed DOI

Rodriguez A., Vigorito E., Clare S., Warren M.V., Couttet P., Soond D.R., van Dongen S., Grocock R.J., Das P.P., Miska E.A., et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316:608–611. doi: 10.1126/science.1139253. PubMed DOI PMC

Vigorito E., Perks K.L., Abreu-Goodger C., Bunting S., Xiang Z., Kohlhaas S., Das P.P., Miska E.A., Rodriguez A., Bradley A., et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity. 2007;27:847–859. doi: 10.1016/j.immuni.2007.10.009. PubMed DOI PMC

Johanson T.M., Skinner J.P., Kumar A., Zhan Y., Lew A.M., Chong M.M. The role of microRNAs in lymphopoiesis. Int. J. Hematol. 2014;100:246–253. doi: 10.1007/s12185-014-1606-y. PubMed DOI

Ranganath P. MicroRNA-155 and Its Role in Malignant Hematopoiesis. Biomark. Insights. 2015;10:95–102. doi: 10.4137/BMI.S27676. PubMed DOI PMC

Sun J.F., Zhang D., Gao C.J., Zhang Y.W., Dai Q.S. Exosome-Mediated MiR-155 Transfer Contributes to Hepatocellular Carcinoma Cell Proliferation by Targeting PTEN. Med. Sci. Monit. Basic Res. 2019;25:218–228. doi: 10.12659/MSMBR.918134. PubMed DOI PMC

Chang S., Wang R.H., Akagi K., Kim K.A., Martin B.K., Cavallone L., Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab) Haines D.C., Basik M., Mai P., et al. Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat. Med. 2011;17:1275–1282. doi: 10.1038/nm.2459. PubMed DOI PMC

Zhao H., Zhang J., Shao H., Liu J., Jin M., Chen J., Huang Y. Transforming Growth Factor beta1/Smad4 Signaling Affects Osteoclast Differentiation via Regulation of miR-155 Expression. Mol. Cells. 2017;40:211–221. doi: 10.14348/molcells.2017.2303. PubMed DOI PMC

Gerloff D., Grundler R., Wurm A.A., Brauer-Hartmann D., Katzerke C., Hartmann J.U., Madan V., Muller-Tidow C., Duyster J., Tenen D.G., et al. NF-kappaB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund. 2015;29:535–547. doi: 10.1038/leu.2014.231. PubMed DOI PMC

Van Roosbroeck K., Fanini F., Setoyama T., Ivan C., Rodriguez-Aguayo C., Fuentes-Mattei E., Xiao L., Vannini I., Redis R.S., D’Abundo L., et al. Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin. Cancer Res. 2017;23:2891–2904. doi: 10.1158/1078-0432.CCR-16-1025. PubMed DOI PMC

Cheung S.T., So E.Y., Chang D., Ming-Lum A., Mui A.L. Interleukin-10 inhibits lipopolysaccharide induced miR-155 precursor stability and maturation. PLoS ONE. 2013;8:e71336. doi: 10.1371/journal.pone.0071336. PubMed DOI PMC

McCoy C.E., Sheedy F.J., Qualls J.E., Doyle S.L., Quinn S.R., Murray P.J., O’Neill L.A. IL-10 inhibits miR-155 induction by toll-like receptors. J. Biol. Chem. 2010;285:20492–20498. doi: 10.1074/jbc.M110.102111. PubMed DOI PMC

Yang M., Shen H., Qiu C., Ni Y., Wang L., Dong W., Liao Y., Du J. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur. J. Cancer. 2013;49:604–615. doi: 10.1016/j.ejca.2012.09.031. PubMed DOI

Kong W., He L., Richards E.J., Challa S., Xu C.X., Permuth-Wey J., Lancaster J.M., Coppola D., Sellers T.A., Djeu J.Y., et al. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. Oncogene. 2014;33:679–689. doi: 10.1038/onc.2012.636. PubMed DOI PMC

Cui B., Chen L., Zhang S., Mraz M., Fecteau J.F., Yu J., Ghia E.M., Zhang L., Bao L., Rassenti L.Z., et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood. 2014;124:546–554. doi: 10.1182/blood-2014-03-559690. PubMed DOI PMC

Eis P.S., Tam W., Sun L., Chadburn A., Li Z., Gomez M.F., Lund E., Dahlberg J.E. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. USA. 2005;102:3627–3632. doi: 10.1073/pnas.0500613102. PubMed DOI PMC

Jiang S., Zhang H.W., Lu M.H., He X.H., Li Y., Gu H., Liu M.F., Wang E.D. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010;70:3119–3127. doi: 10.1158/0008-5472.CAN-09-4250. PubMed DOI

Mattiske S., Suetani R.J., Neilsen P.M., Callen D.F. The oncogenic role of miR-155 in breast cancer. Cancer Epidemiol. Biomark. Prev. 2012;21:1236–1243. doi: 10.1158/1055-9965.EPI-12-0173. PubMed DOI

Zhou Y., Wang X., Liu Z., Huang X., Li X., Cheng K., Jiang X. Prognostic role of microRNA-155 expression in gliomas: A meta-analysis. Clin. Neurol. Neurosurg. 2019;176:103–109. doi: 10.1016/j.clineuro.2018.12.005. PubMed DOI

Haasch D., Chen Y.W., Reilly R.M., Chiou X.G., Koterski S., Smith M.L., Kroeger P., McWeeny K., Halbert D.N., Mollison K.W., et al. T cell activation induces a noncoding RNA transcript sensitive to inhibition by immunosuppressant drugs and encoded by the proto-oncogene, BIC. Cell. Immunol. 2002;217:78–86. doi: 10.1016/S0008-8749(02)00506-3. PubMed DOI

O’Connell R.M., Taganov K.D., Boldin M.P., Cheng G., Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. USA. 2007;104:1604–1609. doi: 10.1073/pnas.0610731104. PubMed DOI PMC

Ruggiero T., Trabucchi M., De Santa F., Zupo S., Harfe B.D., McManus M.T., Rosenfeld M.G., Briata P., Gherzi R. LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2009;23:2898–2908. doi: 10.1096/fj.09-131342. PubMed DOI

Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA. 2006;103:12481–12486. doi: 10.1073/pnas.0605298103. PubMed DOI PMC

Tili E., Michaille J.J., Cimino A., Costinean S., Dumitru C.D., Adair B., Fabbri M., Alder H., Liu C.G., Calin G.A., et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 2007;179:5082–5089. doi: 10.4049/jimmunol.179.8.5082. PubMed DOI

Martinez-Nunez R.T., Louafi F., Friedmann P.S., Sanchez-Elsner T. MicroRNA-155 modulates the pathogen binding ability of dendritic cells (DCs) by down-regulation of DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN) J. Biol. Chem. 2009;284:16334–16342. doi: 10.1074/jbc.M109.011601. PubMed DOI PMC

Koch M., Mollenkopf H.J., Klemm U., Meyer T.F. Induction of microRNA-155 is TLR- and type IV secretion system-dependent in macrophages and inhibits DNA-damage induced apoptosis. Proc. Natl. Acad. Sci. USA. 2012;109:E1153–E1162. doi: 10.1073/pnas.1116125109. PubMed DOI PMC

Wang L., Zhang H., Rodriguez S., Cao L., Parish J., Mumaw C., Zollman A., Kamoka M.M., Mu J., Chen D.Z., et al. Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-kappaB-dependent manner. Cell Stem Cell. 2014;15:51–65. doi: 10.1016/j.stem.2014.04.021. PubMed DOI PMC

Jin H.M., Kim T.J., Choi J.H., Kim M.J., Cho Y.N., Nam K.I., Kee S.J., Moon J.B., Choi S.Y., Park D.J., et al. MicroRNA-155 as a proinflammatory regulator via SHIP-1 down-regulation in acute gouty arthritis. Arthritis Res. Ther. 2014;16:R88. doi: 10.1186/ar4531. PubMed DOI PMC

Sallusto F., Lanzavecchia A. The instructive role of dendritic cells on T-cell responses. Arthritis Res. 2002;4:S127–S132. doi: 10.1186/ar567. PubMed DOI PMC

Ceppi M., Pereira P.M., Dunand-Sauthier I., Barras E., Reith W., Santos M.A., Pierre P. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc. Natl. Acad. Sci. USA. 2009;106:2735–2740. doi: 10.1073/pnas.0811073106. PubMed DOI PMC

Hodge J., Wang F., Wang J., Liu Q., Saaoud F., Wang Y., Singh U.P., Chen H., Luo M., Ai W., et al. Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer. Oncoimmunology. 2020;9:1724761. doi: 10.1080/2162402X.2020.1724761. PubMed DOI PMC

Lu C., Huang X., Zhang X., Roensch K., Cao Q., Nakayama K.I., Blazar B.R., Zeng Y., Zhou X. miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood. 2011;117:4293–4303. doi: 10.1182/blood-2010-12-322503. PubMed DOI PMC

Thai T.H., Calado D.P., Casola S., Ansel K.M., Xiao C., Xue Y., Murphy A., Frendewey D., Valenzuela D., Kutok J.L., et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316:604–608. doi: 10.1126/science.1141229. PubMed DOI

Wang J., Iwanowycz S., Yu F., Jia X., Leng S., Wang Y., Li W., Huang S., Ai W., Fan D. microRNA-155 deficiency impairs dendritic cell function in breast cancer. Oncoimmunology. 2016;5:e1232223. doi: 10.1080/2162402X.2016.1232223. PubMed DOI PMC

Dunand-Sauthier I., Santiago-Raber M.L., Capponi L., Vejnar C.E., Schaad O., Irla M., Seguin-Estevez Q., Descombes P., Zdobnov E.M., Acha-Orbea H., et al. Silencing of c-Fos expression by microRNA-155 is critical for dendritic cell maturation and function. Blood. 2011;117:4490–4500. doi: 10.1182/blood-2010-09-308064. PubMed DOI

Montecalvo A., Larregina A.T., Shufesky W.J., Stolz D.B., Sullivan M.L., Karlsson J.M., Baty C.J., Gibson G.A., Erdos G., Wang Z., et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood. 2012;119:756–766. doi: 10.1182/blood-2011-02-338004. PubMed DOI PMC

Hiramoto J.S., Tsung K., Bedolli M., Norton J.A., Hirose R. Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-gamma and interleukin-12. J. Surg. Res. 2004;116:64–69. doi: 10.1016/j.jss.2003.09.006. PubMed DOI

Asadirad A., Baghaei K., Hashemi S.M., Dehnavi S., Ghanbarian H., Mortaz E., Anissian A., Asadzadeh Aghdaei H., Amani D. Dendritic cell immunotherapy with miR-155 enriched tumor-derived exosome suppressed cancer growth and induced antitumor immune responses in murine model of colorectal cancer induced by CT26 cell line. Int. Immunopharmacol. 2022;104:108493. doi: 10.1016/j.intimp.2021.108493. PubMed DOI

Larionova I., Tuguzbaeva G., Ponomaryova A., Stakheyeva M., Cherdyntseva N., Pavlov V., Choinzonov E., Kzhyshkowska J. Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers. Front. Oncol. 2020;10:566511. doi: 10.3389/fonc.2020.566511. PubMed DOI PMC

Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56:4625–4629. PubMed

Steidl C., Lee T., Shah S.P., Farinha P., Han G., Nayar T., Delaney A., Jones S.J., Iqbal J., Weisenburger D.D., et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N. Engl. J. Med. 2010;362:875–885. doi: 10.1056/NEJMoa0905680. PubMed DOI PMC

DeNardo D.G., Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 2019;19:369–382. doi: 10.1038/s41577-019-0127-6. PubMed DOI PMC

O’Connell R.M., Chaudhuri A.A., Rao D.S., Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl. Acad. Sci. USA. 2009;106:7113–7118. doi: 10.1073/pnas.0902636106. PubMed DOI PMC

Cai X., Yin Y., Li N., Zhu D., Zhang J., Zhang C.Y., Zen K. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J. Mol. Cell Biol. 2012;4:341–343. doi: 10.1093/jmcb/mjs044. PubMed DOI

Rauh M.J., Ho V., Pereira C., Sham A., Sly L.M., Lam V., Huxham L., Minchinton A.I., Mui A., Krystal G. SHIP represses the generation of alternatively activated macrophages. Immunity. 2005;23:361–374. doi: 10.1016/j.immuni.2005.09.003. PubMed DOI

Zheng P., Chen L., Yuan X., Luo Q., Liu Y., Xie G., Ma Y., Shen L. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J. Exp. Clin. Cancer Res. 2017;36:53. doi: 10.1186/s13046-017-0528-y. PubMed DOI PMC

Wu Q., Sun S., Li Z., Yang Q., Li B., Zhu S., Wang L., Wu J., Yuan J., Yang C., et al. Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression. Mol. Cancer. 2018;17:155. doi: 10.1186/s12943-018-0899-5. PubMed DOI PMC

Zhou X., Yan T., Huang C., Xu Z., Wang L., Jiang E., Wang H., Chen Y., Liu K., Shao Z., et al. Melanoma cell-secreted exosomal miR-155-5p induce proangiogenic switch of cancer-associated fibroblasts via SOCS1/JAK2/STAT3 signaling pathway. J. Exp. Clin. Cancer Res. 2018;37:242. doi: 10.1186/s13046-018-0911-3. PubMed DOI PMC

Veglia F., Sanseviero E., Gabrilovich D.I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 2021;21:485–498. doi: 10.1038/s41577-020-00490-y. PubMed DOI PMC

Ai L., Mu S., Wang Y., Wang H., Cai L., Li W., Hu Y. Prognostic role of myeloid-derived suppressor cells in cancers: A systematic review and meta-analysis. BMC Cancer. 2018;18:1220. doi: 10.1186/s12885-018-5086-y. PubMed DOI PMC

Wang J., Yu F., Jia X., Iwanowycz S., Wang Y., Huang S., Ai W., Fan D. MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int. J. Cancer. 2015;136:E602–E613. doi: 10.1002/ijc.29151. PubMed DOI PMC

Kim S., Song J.H., Kim S., Qu P., Martin B.K., Sehareen W.S., Haines D.C., Lin P.C., Sharan S.K., Chang S. Loss of oncogenic miR-155 in tumor cells promotes tumor growth by enhancing C/EBP-beta-mediated MDSC infiltration. Oncotarget. 2016;7:11094–11112. doi: 10.18632/oncotarget.7150. PubMed DOI PMC

Li L., Zhang J., Diao W., Wang D., Wei Y., Zhang C.Y., Zen K. MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J. Immunol. 2014;192:1034–1043. doi: 10.4049/jimmunol.1301309. PubMed DOI

Chen S., Wang L., Fan J., Ye C., Dominguez D., Zhang Y., Curiel T.J., Fang D., Kuzel T.M., Zhang B. Host miR155 promotes tumor growth through a myeloid-derived suppressor cell-dependent mechanism. Cancer Res. 2015;75:519–531. doi: 10.1158/0008-5472.CAN-14-2331. PubMed DOI PMC

Bruns H., Bottcher M., Qorraj M., Fabri M., Jitschin S., Dindorf J., Busch L., Jitschin R., Mackensen A., Mougiakakos D. CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D. Leuk. Off. J. Leuk. Soc. Am. Leuk. Res. Fund. 2017;31:985–988. doi: 10.1038/leu.2016.378. PubMed DOI

Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., McKenna D., Le C., Defor T.E., Burns L.J., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105:3051–3057. doi: 10.1182/blood-2004-07-2974. PubMed DOI

Waldhauer I., Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27:5932–5943. doi: 10.1038/onc.2008.267. PubMed DOI

Trotta R., Chen L., Ciarlariello D., Josyula S., Mao C., Costinean S., Yu L., Butchar J.P., Tridandapani S., Croce C.M., et al. miR-155 regulates IFN-gamma production in natural killer cells. Blood. 2012;119:3478–3485. doi: 10.1182/blood-2011-12-398099. PubMed DOI PMC

Kandell W.M., Donatelli S.S., Trinh T.L., Calescibetta A.R., So T., Tu N., Gilvary D.L., Chen X., Cheng P., Adams W.A., et al. MicroRNA-155 governs SHIP-1 expression and localization in NK cells and regulates subsequent infiltration into murine AT3 mammary carcinoma. PLoS ONE. 2020;15:e0225820. doi: 10.1371/journal.pone.0225820. PubMed DOI PMC

Jovanovic M.Z., Geller D.A., Gajovic N.M., Jurisevic M.M., Arsenijevic N.N., Jovanovic M.M., Supic G.M., Vojvodic D.V., Jovanovic I.P. Dual blockage of PD-L/PD-1 and IL33/ST2 axes slows tumor growth and improves antitumor immunity by boosting NK cells. Life Sci. 2022;289:120214. doi: 10.1016/j.lfs.2021.120214. PubMed DOI

O’Connell R.M., Rao D.S., Chaudhuri A.A., Boldin M.P., Taganov K.D., Nicoll J., Paquette R.L., Baltimore D. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J. Exp. Med. 2008;205:585–594. doi: 10.1084/jem.20072108. PubMed DOI PMC

Turner M., Vigorito E. Regulation of B- and T-cell differentiation by a single microRNA. Biochem. Soc. Trans. 2008;36:531–533. doi: 10.1042/BST0360531. PubMed DOI

O’Connell R.M., Rao D.S., Chaudhuri A.A., Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 2010;10:111–122. doi: 10.1038/nri2708. PubMed DOI

Escobar T., Yu C.R., Muljo S.A., Egwuagu C.E. STAT3 activates miR-155 in Th17 cells and acts in concert to promote experimental autoimmune uveitis. Investig. Ophthalmol. Vis. Sci. 2013;54:4017–4025. doi: 10.1167/iovs.13-11937. PubMed DOI PMC

Ho I.C., Lo D., Glimcher L.H. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. J. Exp. Med. 1998;188:1859–1866. doi: 10.1084/jem.188.10.1859. PubMed DOI PMC

Banerjee A., Schambach F., DeJong C.S., Hammond S.M., Reiner S.L. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur. J. Immunol. 2010;40:225–231. doi: 10.1002/eji.200939381. PubMed DOI PMC

Goncalves-Alves E., Saferding V., Schliehe C., Benson R., Kurowska-Stolarska M., Brunner J.S., Puchner A., Podesser B.K., Smolen J.S., Redlich K., et al. MicroRNA-155 Controls T Helper Cell Activation During Viral Infection. Front. Immunol. 2019;10:1367. doi: 10.3389/fimmu.2019.01367. PubMed DOI PMC

Li C., Jiang P., Wei S., Xu X., Wang J. Regulatory T cells in tumor microenvironment: New mechanisms, potential therapeutic strategies and future prospects. Mol. Cancer. 2020;19:116. doi: 10.1186/s12943-020-01234-1. PubMed DOI PMC

Laine A., Labiad O., Hernandez-Vargas H., This S., Sanlaville A., Leon S., Dalle S., Sheppard D., Travis M.A., Paidassi H., et al. Regulatory T cells promote cancer immune-escape through integrin alphavbeta8-mediated TGF-beta activation. Nat. Commun. 2021;12:6228. doi: 10.1038/s41467-021-26352-2. PubMed DOI PMC

Kohlhaas S., Garden O.A., Scudamore C., Turner M., Okkenhaug K., Vigorito E. Cutting edge: The Foxp3 target miR-155 contributes to the development of regulatory T cells. J. Immunol. 2009;182:2578–2582. doi: 10.4049/jimmunol.0803162. PubMed DOI

Lu L.F., Thai T.H., Calado D.P., Chaudhry A., Kubo M., Tanaka K., Loeb G.B., Lee H., Yoshimura A., Rajewsky K., et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2009;30:80–91. doi: 10.1016/j.immuni.2008.11.010. PubMed DOI PMC

Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D., Levine S.S., Fraenkel E., von Boehmer H., Young R.A. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature. 2007;445:931–935. doi: 10.1038/nature05478. PubMed DOI PMC

Zheng Y., Josefowicz S.Z., Kas A., Chu T.T., Gavin M.A., Rudensky A.Y. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature. 2007;445:936–940. doi: 10.1038/nature05563. PubMed DOI

Heyn J., Luchting B., Hinske L.C., Hubner M., Azad S.C., Kreth S. miR-124a and miR-155 enhance differentiation of regulatory T cells in patients with neuropathic pain. J. Neuroinflamm. 2016;13:248. doi: 10.1186/s12974-016-0712-6. PubMed DOI PMC

Zhu F., Li H., Liu Y., Tan C., Liu X., Fan H., Wu H., Dong Y., Yu T., Chu S., et al. miR-155 antagomir protect against DSS-induced colitis in mice through regulating Th17/Treg cell balance by Jarid2/Wnt/beta-catenin. Biomed. Pharmacother. Biomed. Pharmacother. 2020;126:109909. doi: 10.1016/j.biopha.2020.109909. PubMed DOI

Raskov H., Orhan A., Christensen J.P., Gogenur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br. J. Cancer. 2021;124:359–367. doi: 10.1038/s41416-020-01048-4. PubMed DOI PMC

Dudda J.C., Salaun B., Ji Y., Palmer D.C., Monnot G.C., Merck E., Boudousquie C., Utzschneider D.T., Escobar T.M., Perret R., et al. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity. 2013;38:742–753. doi: 10.1016/j.immuni.2012.12.006. PubMed DOI PMC

Shiravand Y., Khodadadi F., Kashani S.M.A., Hosseini-Fard S.R., Hosseini S., Sadeghirad H., Ladwa R., O’Byrne K., Kulasinghe A. Immune Checkpoint Inhibitors in Cancer Therapy. Curr. Oncol. 2022;29:3044–3060. doi: 10.3390/curroncol29050247. PubMed DOI PMC

Hargadon K.M., Johnson C.E., Williams C.J. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol. 2018;62:29–39. doi: 10.1016/j.intimp.2018.06.001. PubMed DOI

Yee D., Shah K.M., Coles M.C., Sharp T.V., Lagos D. MicroRNA-155 induction via TNF-alpha and IFN-gamma suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. J. Biol. Chem. 2017;292:20683–20693. doi: 10.1074/jbc.M117.809053. PubMed DOI PMC

Renrick A.N., Thounaojam M.C., de Aquino M.T.P., Chaudhuri E., Pandhare J., Dash C., Shanker A. Bortezomib Sustains T Cell Function by Inducing miR-155-Mediated Downregulation of SOCS1 and SHIP1. Front. Immunol. 2021;12:607044. doi: 10.3389/fimmu.2021.607044. PubMed DOI PMC

Wang J., Wang Q., Guan Y., Sun Y., Wang X., Lively K., Wang Y., Luo M., Kim J.A., Murphy E.A., et al. Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and anti-tumor function. J. Clin. Investig. 2022;132:e157248. doi: 10.1172/JCI157248. PubMed DOI PMC

Nguyen M.T., Luo Y.H., Li A.L., Tsai J.C., Wu K.L., Chung P.J., Ma N. miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma. Biomolecules. 2021;11:1648. doi: 10.3390/biom11111648. PubMed DOI PMC

Liu L., Yi H., He H., Pan H., Cai L., Ma Y. Tumor associated macrophage-targeted microRNA delivery with dual-responsive polypeptide nanovectors for anti-cancer therapy. Biomaterials. 2017;134:166–179. doi: 10.1016/j.biomaterials.2017.04.043. PubMed DOI

Bayraktar R., Van Roosbroeck K. miR-155 in cancer drug resistance and as target for miRNA-based therapeutics. Cancer Metastasis Rev. 2018;37:33–44. doi: 10.1007/s10555-017-9724-7. PubMed DOI

Kopp K.L., Ralfkiaer U., Gjerdrum L.M., Helvad R., Pedersen I.H., Litman T., Jonson L., Hagedorn P.H., Krejsgaard T., Gniadecki R., et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle. 2013;12:1939–1947. doi: 10.4161/cc.24987. PubMed DOI PMC

Strizova Z., Snajdauf M., Stakheev D., Taborska P., Vachtenheim J., Jr., Biskup J., Lischke R., Bartunkova J., Smrz D. The paratumoral immune cell signature reveals the potential for the implementation of immunotherapy in esophageal carcinoma patients. J. Cancer Res. Clin. Oncol. 2020;146:1979–1992. doi: 10.1007/s00432-020-03258-y. PubMed DOI PMC

Strizova Z., Taborska P., Stakheev D., Partlova S., Havlova K., Vesely S., Bartunkova J., Smrz D. NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma. Urol. Oncol. 2019;37:503–509. doi: 10.1016/j.urolonc.2019.03.014. PubMed DOI

Kuchar M., Strizova Z., Votava M., Plzak J. The relevance of Fas/Fas ligand axis in the tumor microenvironment of salivary gland adenoid cystic carcinoma. Oral Oncol. 2019;97:135–136. doi: 10.1016/j.oraloncology.2019.08.015. PubMed DOI

Strizova Z., Bartunkova J., Smrz D. The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma. Cancer Immunol. Immunother. 2019;68:1831–1838. doi: 10.1007/s00262-019-02359-z. PubMed DOI PMC

Das S., Camphausen K., Shankavaram U. Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies. Cancers. 2020;12:2476. doi: 10.3390/cancers12092476. PubMed DOI PMC